Bicara Therapeutics Inc.
BCAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Valued at $1.13B, BCAX is a small-cap name in its sector. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Market Cap
$1.13B
Beta
-0.69
P/E (TTM)
—
P/E (Fwd)
-4.85
EPS (TTM)
$-3.08
EPS (Fwd)
$-3.52
ROE
-41.0%
ROA
-26.1%
Cash
$497.3M
Total Debt
$1.2M
Free CF
-$76.9M
52W Change
0.4%
Annual Financials
Cash vs Debt
Where BCAX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, BCAX finished 26.37% below its 150-day moving average ($22.79) and 21.22% below its 200-day moving average ($21.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCAX overbought or oversold?
At the October 19, 2026 close, BCAX's RSI(14) was 29.2, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bicara Therapeutics Inc. holds $497.3M in cash against $1.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$76.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -41.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Bicara Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, BCAX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing BCAX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.